Vaanaa and Medeze laboratory — recognised regional leaders in cell therapy since 2010
Vaanaa is among Asia's first and Thailand's largest anti-ageing and regenerative medicine clinics — with a full biotech laboratory on site, oncology treatment protocols and luxury medical tourism.
Our mission is to deliver personalised restorative and preventive care with precision and dedication to excellence. Every treatment is built on the latest advances in regenerative medicine and precisely matched to your biology, goals and lifestyle.
Our vision is to become Asia's leading destination for personalised restorative wellness — combining scientific innovation with serene luxury.
«We were the first biotechnology laboratory in the world to begin biobanking and using autologous stem cells. 30,000 patients have entrusted their cells to us.»
Founders of Vaanaa & Medeze Group
Medeze Group is a publicly listed biotechnology company, our laboratory partner and scientific backbone. The largest cell banking laboratory in Southeast Asia.
Founded as 'Bangkok Stem Cell Bank'
World's first MSC banking from adipose tissue (FAT)
Class 100 laboratory — largest in SEA
Rebranded as MEDEZE. First Frost & Sullivan award
Vaanaa Longevity Clinic founded. Revenue grew 51%
IPO. Frost & Sullivan Best Company SEA
Top Cell & Gene Therapy Company APAC (Life Sciences Review)
Cleanrooms with 0.5-micron particle control. NEBB-certified (USA). Largest of its kind in Southeast Asia. Operations comply with FTACR, AABB and cGMP.
Among the few in the world using AI robotics in the biobank to grow the highest-quality cells. Automated AXP AutoXpress® processing system.
The only private participant in Thailand Ministry of Public Health's ATMPs Sandbox programme. Pilot clinical trials at Bangrak Medical Center.
According to the CEO WORLD Healthcare Index (2023), Thailand ranks 13th out of 89 countries — ahead of Norway (15), Germany (17), Switzerland (18) and the USA (30). In this index, a lower number means higher quality.
Thailand is a top-5 medical tourism destination globally (MTI 2020-2021, 46 countries). A leader in cellular technology, anti-ageing medicine and regenerative surgery.
Global stem cell market: $19B (2024) → $40B (2030), CAGR 11%. NK cell market: $3.2B → $8.6B by 2033, CAGR 11.8%. Thailand is at the forefront of this growth.
400+ international-standard private clinics
Biotech market: $124M → $249M by 2030
VIP Fast Track at Suvarnabhumi Airport